Skip to main content

Moderate Hypofractionation Shows Good Safety Outcomes in Breast Cancer

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 16, 2024.

via HealthDay

MONDAY, Sept. 16, 2024 -- For patients with breast cancer, moderate hypofractionation (MHF) shows an improved safety profile, cosmesis, and quality of life compared with conventional fractionation (CF), with equivalent oncologic outcomes, according to a study published online Sept. 11 in The BMJ.

Shing Fung Lee, M.B.B.S., from the National University Hospital in Singapore, and colleagues conducted a systematic review and meta-analysis of randomized controlled trials focusing on CF (daily fractions of 1.8 to 2 Gy reaching 50 to 50.4 Gy), MHF (2.65 to 3.3 Gy for 13 to 16 fractions), and/or ultra-hypofractionation (UHF; schedule of five fractions) for breast cancer. Fifty-nine articles representing 35 trials with 20,237 patients were assessed.

The researchers found that for MHF versus CF, the risk ratios for grade ≥2 acute radiation dermatitis were 0.54 and 0.68 following breast-conserving therapy and mastectomy, respectively. Hyperpigmentation and grade ≥2 breast shrinkage occurred less often after MHF than CF, with risk ratios of 0.77 and 0.92, respectively, in the combined breast-conserving therapy and mastectomy population. Differences in hyperpigmentation and breast shrinkage were not statistically significant in the breast-conserving therapy-only trials. For breast-conserving therapy and mastectomy populations combined, the risk ratio for grade ≥2 acute radiation dermatitis was not significantly different for UHF versus MHF. Compared with CF, MHF was associated with improved cosmesis and quality of life, while data on UHF were less conclusive. Similar survival and recurrence outcomes were seen for UHF, MHF, and CF.

"These findings justify the wider adoption of moderate hypofractionation as the preferred approach, given its balance of therapeutic efficacy and improved safety," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Childhood Cancer Treatment, Genetics Contribute to Subsequent Neoplasm Risk

FRIDAY, June 13, 2025 -- Cancer treatments and genetic predisposition contribute to the risk of subsequent neoplasms (SNs) among long-term childhood cancer survivors, according to...

Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease

THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...

Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer

THURSDAY, June 5, 2025 -- For patients with node-positive breast cancer who become pathologically tumor-free with negative axillary nodes (ypN0) after neoadjuvant chemotherapy...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.